CN1946402A - 用作ccr3拮抗剂的哌啶衍生物 - Google Patents

用作ccr3拮抗剂的哌啶衍生物 Download PDF

Info

Publication number
CN1946402A
CN1946402A CNA2005800121378A CN200580012137A CN1946402A CN 1946402 A CN1946402 A CN 1946402A CN A2005800121378 A CNA2005800121378 A CN A2005800121378A CN 200580012137 A CN200580012137 A CN 200580012137A CN 1946402 A CN1946402 A CN 1946402A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
compound
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800121378A
Other languages
English (en)
Chinese (zh)
Inventor
P·C·亭
J·曹
Y·董
E·J·吉尔伯特
Y·黄
J·M·凯利
S·麦库姆比
N·-Y·施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1946402A publication Critical patent/CN1946402A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800121378A 2004-02-05 2005-02-02 用作ccr3拮抗剂的哌啶衍生物 Pending CN1946402A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54201304P 2004-02-05 2004-02-05
US60/542,013 2004-02-05

Publications (1)

Publication Number Publication Date
CN1946402A true CN1946402A (zh) 2007-04-11

Family

ID=34860249

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800121378A Pending CN1946402A (zh) 2004-02-05 2005-02-02 用作ccr3拮抗剂的哌啶衍生物

Country Status (9)

Country Link
US (1) US7705153B2 (https=)
EP (1) EP1725235B1 (https=)
JP (1) JP2007520556A (https=)
CN (1) CN1946402A (https=)
AT (1) ATE428422T1 (https=)
CA (1) CA2554465A1 (https=)
DE (1) DE602005013931D1 (https=)
ES (1) ES2324224T3 (https=)
WO (1) WO2005077369A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388032A (zh) * 2009-04-08 2012-03-21 贝林格尔.英格海姆国际有限公司 作为ccr3拮抗剂的取代的哌啶
CN112250611A (zh) * 2020-11-27 2021-01-22 济南大学 一种-2-(2,5-二氟苯基)吡咯烷盐酸盐的合成方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006100190A (ru) * 2003-06-13 2006-08-10 Шеринг Акциенгезельшафт (De) Производные хинолиламида в качестве антагонистов ccr-5
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CN101460482B (zh) * 2006-03-21 2013-03-27 默沙东公司 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物
MX2009000577A (es) * 2006-07-14 2009-03-09 Schering Corp Compuestos de piperazina sustituida heterociclica con actividad antagonista de cxcr3.
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012171863A1 (en) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
KR20160098424A (ko) 2013-12-19 2016-08-18 바이엘 파마 악티엔게젤샤프트 치환된 피페리디닐-테트라히드로퀴놀린
EP3083610A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
CR20160276A (es) 2013-12-19 2016-10-20 Bayer Pharma AG "piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c"
US20160318866A1 (en) 2013-12-19 2016-11-03 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN110636844A (zh) 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
PL233595B1 (pl) 2017-05-12 2019-11-29 Celon Pharma Spolka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
KR0171169B1 (ko) * 1996-01-20 1999-03-30 구자홍 엘시디 패널 구동을 위한 다계조 전압 발생 회로
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
SK287418B6 (sk) * 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
JP4303969B2 (ja) * 2001-03-29 2009-07-29 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン
AR033452A1 (es) * 2001-03-29 2003-12-17 Schering Corp Antagonistas de ccr5 utiles para el tratamiento del sida

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388032A (zh) * 2009-04-08 2012-03-21 贝林格尔.英格海姆国际有限公司 作为ccr3拮抗剂的取代的哌啶
TWI466880B (zh) * 2009-04-08 2015-01-01 Boehringer Ingelheim Int 作為ｃｃｒ３拮抗劑之經取代哌啶
CN102388032B (zh) * 2009-04-08 2015-01-14 贝林格尔.英格海姆国际有限公司 作为ccr3拮抗剂的取代的哌啶
CN112250611A (zh) * 2020-11-27 2021-01-22 济南大学 一种-2-(2,5-二氟苯基)吡咯烷盐酸盐的合成方法

Also Published As

Publication number Publication date
JP2007520556A (ja) 2007-07-26
US20050182095A1 (en) 2005-08-18
WO2005077369A1 (en) 2005-08-25
CA2554465A1 (en) 2005-08-25
ATE428422T1 (de) 2009-05-15
ES2324224T3 (es) 2009-08-03
US7705153B2 (en) 2010-04-27
EP1725235A1 (en) 2006-11-29
DE602005013931D1 (https=) 2009-05-28
EP1725235B1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
CN1946402A (zh) 用作ccr3拮抗剂的哌啶衍生物
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1304382C (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
CN1243751C (zh) 用作抗变态反应药物的哌啶化合物
CN1280269C (zh) 脂肪族含氮五员环化合物
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN1296346C (zh) 酰化的6,7,8,9－四氢－5h－苯并环庚烯基胺和它们作为药物的用途
CN1662524A (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN1658875A (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
CN1592739A (zh) 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
CN1142910C (zh) 酰胺化合物
CN1585749A (zh) 类大麻苷受体配体
CN1658874A (zh) 用作组胺h3拮抗剂的(1－4－哌啶基)苯并咪唑衍生物
CN1088917A (zh) 取代的苄氨基含氮非芳族杂环化合物
CN1290251A (zh) N－酰基环胺衍生物
CN1440393A (zh) 环状化合物
CN1761646A (zh) 大麻素受体配位体
CN1633433A (zh) N－芳酰基环胺
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1483030A (zh) 用于治疗神经系统疾病的酰胺烷基哌啶和酰胺烷基哌嗪衍生物
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN101065376A (zh) 2－酰胺基－4－苯基噻唑衍生物、它们的制备与治疗应用
HK1039124A1 (en) Phthalzaine derivatives phosphodiesterase 4 inhibitors
CN1152879C (zh) 萘啶衍生物
CN1114591C (zh) 环酰胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication